Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- ...

Objectives C reactive protein (CRP) is frequently normal in psoriatic arthritis (PsA) despite active disease, complicating ...

The FDA has approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya) for adults with moderately to severely ...

Horsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) ...

Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has approved a subcutaneous induction regimen of TREMFYA for the treatment ...

Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to ...

Developed by Johnson & Johnson, guselkumab is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

Trinity College Dublin scientists showed that electrical stimulation reprograms macrophages to reduce inflammation and boost healing. This breakthrough could lead to broad therapeutic uses.

In almost all solid tumors—i.e. cancers with a solid tissue structure—the detection of tumor cells in the lymph nodes is ...

Objectives The development of simple tools to identify individuals at high risk of coronary heart disease (CHD) would enable rapid implementation of preventive measures. This study was designed to ...

Wang, Z. and Wang, B. (2025) Impact of Glycemic Variability on Prognosis in Sepsis Patients. Journal of Biosciences and ...